Nervgen Pharma (NGEN) Liabilities and Shareholders Equity (2024 - 2026)

Nervgen Pharma (NGEN) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $15.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $15.1 million; the TTM figure through Mar 2026 stood at $45.7 million (changed N/A YoY), while the FY2025 annual figure was $16.6 million, up 19.31% from the prior year.
• Liabilities and Shareholders Equity slipped to $15.1 million in Q1 2026 per NGEN's latest filing, from $16.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $16.6 million in Q4 2025 and bottomed at $13.9 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $15.2 million across 3 years, with a median of $15.1 million in 2026.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 19.31% in 2025 and fell as far as 19.31% in 2025.
• Nervgen Pharma's Liabilities and Shareholders Equity stood at $13.9 million in 2024, then grew by 19.31% to $16.6 million in 2025, then fell by 9.02% to $15.1 million in 2026.
• Business Quant data shows NGEN's Liabilities and Shareholders Equity at $15.1 million in Q1 2026, $16.6 million in Q4 2025, and $13.9 million in Q4 2024.